G1 Therapeutics Inc.

23.80-1.31-5.22%Vol 132.96K1Y Perf 80.47%
Apr 16th, 2021 10:33 DELAYED
BID23.80 ASK23.90
Open25.06 Previous Close25.11
Pre-Market- After-Market-
 - -%  - -
Target Price
56.33 
Analyst Rating
Strong Buy 1.00
Potential %
132.77 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-100/-68/-63 
Value Ranking
★★★+     54.32
Insiders Value % 3/6/12 mo.
-100/-69/-69 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-100/-54/-54 
Income Ranking
 —    -
Market Cap998.62M 
Earnings Rating
Sell
Price Range Ratio 52W %
49.47 
Earnings Date
5th May 2021

Today's Price Range

23.8025.06

52W Range

10.8137.07

Summary:

Buy

Technical Indicators: Buy
Moving Averages: Strong Buy
Performance
1 Week
-1.80%
1 Month
13.26%
3 Months
20.55%
6 Months
85.18%
1 Year
80.47%
3 Years
-30.81%
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
GTHX23.80-1.3100-5.22
AAPL134.12-0.3800-0.28
GOOG2 292.22-4.4400-0.19
MSFT259.550.05000.02
XOM56.62-0.3600-0.63
WFC43.150.91002.15
JNJ160.860.47000.29
FB306.56-1.2600-0.41
GE13.47-0.0800-0.59
JPM153.681.51000.99
Earnings HistoryEstimateReportedSurprise %
Q04 2020-0.88-0.6723.86
Q03 2020-0.25-0.31-24.00
Q02 2020-0.83-0.830.00
Q01 2020-0.98-0.8216.33
Q04 2019-0.97-0.943.09
Q03 2019-0.87-0.861.15
Q02 2019-0.73-0.82-12.33
Q01 2019-0.69-0.647.25
Earnings Per EndEstimateRevision %Trend
3/2021 QR-1.09-18.48Negative
6/2021 QR-1.10-19.57Negative
12/2021 FY-4.21-7.40Negative
12/2022 FY-3.41-2.10Negative
Next Report Date5th May 2021
Estimated EPS Next Report-1.09
Estimates Count6
EPS Growth Next 5 Years %-
Volume Overview
Volume132.96K
Shares Outstanding41.96M
Trades Count1.50K
Dollar Volume74.20M
Avg. Volume1.50M
Avg. Weekly Volume471.86K
Avg. Monthly Volume1.07M
Avg. Quarterly Volume1.56M

G1 Therapeutics Inc. (NASDAQ: GTHX) stock closed at 25.11 per share at the end of the most recent trading day (a 1.66% change compared to the prior day closing price) with a volume of 489.72K shares and market capitalization of 998.62M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 122 people. G1 Therapeutics Inc. CEO is John E. Bailey.

The one-year performance of G1 Therapeutics Inc. stock is 80.47%, while year-to-date (YTD) performance is 39.58%. GTHX stock has a five-year performance of %. Its 52-week range is between 10.81 and 37.07, which gives GTHX stock a 52-week price range ratio of 49.47%

G1 Therapeutics Inc. currently has a PE ratio of -9.60, a price-to-book (PB) ratio of 5.97, a price-to-sale (PS) ratio of 22.01, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -36.85%, a ROC of -41.96% and a ROE of -43.58%. The company’s profit margin is -%, its EBITDA margin is -394.50%, and its revenue ttm is $45.29 Million , which makes it $1.08 revenue per share.

Of the last four earnings reports from G1 Therapeutics Inc., there were 2 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-1.09 for the next earnings report. G1 Therapeutics Inc.’s next earnings report date is 05th May 2021.

The consensus rating of Wall Street analysts for G1 Therapeutics Inc. is Strong Buy (1), with a target price of $56.33, which is +132.77% compared to the current price. The earnings rating for G1 Therapeutics Inc. stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

G1 Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

G1 Therapeutics Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 18.64, ATR14 : 2.05, CCI20 : 68.33, Chaikin Money Flow : 0.22, MACD : -0.28, Money Flow Index : 68.18, ROC : 16.63, RSI : 45.23, STOCH (14,3) : 72.57, STOCH RSI : 1.00, UO : 49.76, Williams %R : -27.43), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of G1 Therapeutics Inc. in the last 12-months were: Glenn P. Muir (Buy at a value of $675 000), James S. Hanson (Buy at a value of $14 950), Jennifer K. Moses (Option Excercise at a value of $11 160), John E. Bailey (Buy at a value of $204 750), Mark A. Velleca (Option Excercise at a value of $451 829), Mark A. Velleca (Sold 121 040 shares of value $2 727 498 ), Rajesh K. Malik (Option Excercise at a value of $162 038), Rajesh K. Malik (Sold 48 000 shares of value $1 014 882 ), Seth Rudnick (Sold 53 016 shares of value $1 073 379 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
5 (100.00 %)
5 (100.00 %)
5 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

G1 Therapeutics Inc.

G1 Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel, small-molecule therapies to target unmet needs in the treatment of cancer. The firm is developing drugs that have the potential to treat most types of cancer such as cell lung cancer and breast cancer and designs them to combine - and enhance - the anti-tumor activity of current therapies.

CEO: John E. Bailey

Telephone: +1 919 213-9835

Address: 700 Park Offices Drive, Research Triangle Park 27709, NC, US

Number of employees: 122

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

100%0%

Bearish Bullish

71%29%

Bearish Bullish

50%50%

Bearish Bullish

57%43%

News

Stocktwits